- Home
- ARQT vs ECAT Comparison
ARQT vs ECAT Comparison
Compare ARQT & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ECAT
- Stock Information
- Founded
- ARQT 2016
- ECAT 2021
- Country
- ARQT United States
- ECAT United States
- Employees
- ARQT N/A
- ECAT N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- ARQT Health Care
- ECAT Finance
- Exchange
- ARQT Nasdaq
- ECAT Nasdaq
- Market Cap
- ARQT 2.0B
- ECAT 1.7B
- IPO Year
- ARQT 2020
- ECAT N/A
- Fundamental
- Price
- ARQT $13.80
- ECAT $14.58
- Analyst Decision
- ARQT Strong Buy
- ECAT
- Analyst Count
- ARQT 6
- ECAT 0
- Target Price
- ARQT $18.80
- ECAT N/A
- AVG Volume (30 Days)
- ARQT 2.6M
- ECAT 278.6K
- Earning Date
- ARQT 05-13-2025
- ECAT 01-01-0001
- Dividend Yield
- ARQT N/A
- ECAT 9.20%
- EPS Growth
- ARQT N/A
- ECAT N/A
- EPS
- ARQT N/A
- ECAT 2.39
- Revenue
- ARQT $196,542,000.00
- ECAT N/A
- Revenue This Year
- ARQT $60.21
- ECAT N/A
- Revenue Next Year
- ARQT $40.21
- ECAT N/A
- P/E Ratio
- ARQT N/A
- ECAT $7.15
- Revenue Growth
- ARQT 229.74
- ECAT N/A
- 52 Week Low
- ARQT $6.99
- ECAT $14.02
- 52 Week High
- ARQT $17.75
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- ARQT 46.44
- ECAT 38.62
- Support Level
- ARQT $12.51
- ECAT $14.48
- Resistance Level
- ARQT $13.67
- ECAT $15.30
- Average True Range (ATR)
- ARQT 1.43
- ECAT 0.49
- MACD
- ARQT -0.27
- ECAT -0.02
- Stochastic Oscillator
- ARQT 34.83
- ECAT 47.97
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.